Tuesday marked a day with several major COVID-19 events: 

• Another vaccine trial has been placed on hold. Johnson & Johnson’s study was paused due to unexplained illness in a participant. That vaccine candidate is in the midst of a 60,000-patient clinical trial. 
• The first United States resident confirmed to be reinfected with the coronavirus is a 25-year-old Nevada man. His second infection was considered “more severe“ than the first. However, the man fully recovered both times. This is the fifth documented case of its kind worldwide.
• Finally, the National Institute of Allergy and Infectious Diseases today launched a study designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19. The ACTIV-5 Big Effect Trial will enroll adult volunteers hospitalized with COVID-19 at several sites. More information on that initiative can be found here.